Analysts Set Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) PT at $22.90

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) have been given an average rating of “Buy” by the thirteen brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $23.10.

CMPS has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. BTIG Research reiterated a “buy” rating and set a $14.00 price objective on shares of Compass Pathways in a research note on Wednesday, May 13th. Canaccord Genuity Group lifted their price objective on Compass Pathways from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Friday. Raymond James Financial reiterated a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research note on Monday, April 20th.

Hedge Funds Weigh In On Compass Pathways

Institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its stake in shares of Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after buying an additional 1,920 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways during the 4th quarter valued at about $38,000. Parallel Advisors LLC grew its position in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after acquiring an additional 7,183 shares during the period. Advisory Services Network LLC acquired a new stake in shares of Compass Pathways during the 3rd quarter valued at about $41,000. Finally, North Star Investment Management Corp. grew its position in shares of Compass Pathways by 1,354.0% during the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after acquiring an additional 7,000 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Compass Pathways Stock Performance

Shares of CMPS stock opened at $15.07 on Tuesday. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -4.78 and a beta of 2.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. The business has a fifty day moving average of $11.14 and a 200 day moving average of $8.19. Compass Pathways has a 1 year low of $2.68 and a 1 year high of $15.40.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. As a group, research analysts expect that Compass Pathways will post -1.24 earnings per share for the current year.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.